-
Ocena učinkovitosti prvega zdravljenja z bortezomibom pred avtologno presaditvijo krvotvornih matičnih celic pri diseminiranem plazmocitomu = Effectiveness of first treatment with bortezomib prior to autologous stem cell transplantation for multiple myelomaČernelč, Peter ; Kodre, VeronikaBackground: In this retrospective study we evaluated effectiveness and safety of first- line treatment with bortezomib and dexamethasone in multiple myelomapatients, comparing our results with ... already published clinical studies. Methods: Patients received bortezomib as part of everyday clinical practice and according to the latest guidelines of the Združenje hematologov Slovenije . Patients who were previously treated with first-line VAD (vincristine, doxorubicin modified with farmarubicine, dexamethasone), but dueto uneffectiveness changed the treatment to bortezomib, were also included in the study. In 30 patients effectivenes was evaluated after average 3-4 cycles of bortezomib and dexamethasone according to the modified Southwest Oncology Group criteria. Treatment effectiveness was evaluated according to the previous VAD treatment, renal function and cytogenetic analysis. Side effects and reasons for early treatment discontinuation were described. Results: Patients received 2 to 8 cycles (median 4 cycles) of bortezomib and dexamethasone treatment. After average 3-4 cycles, 80% of patients acheived good treatment response (56.7% very good partial response, 23.3% partial response). We observed that the treatment, renal insufficiency and negative cytogenetic analysis, sionce we observed similar rates of very good partial response ande partial response in patients without previous VAD treatment (82.3% vs. 76.9%), normal renal function (85.7% vs. 75%) and normal cytogenetics (77.8% vs. 80%), although statistical evaluation was not possibledue to small number of patients. The most common side effect was neuropathy (40%) and in 5 patients (16.6%), due to grade 3 or more, the treatment was discontinued. Other side effects were: anemia (26%), infection (166%), thrombocytopenia (10%), neutropenia (6.6%), gastrointestinal problems (23.3%) and herpes zooster (6.6%). (Abstract truncated at 2000 characters).Vir: Zdravniški vestnik : glasilo Slovenskega zdravniškega društva = Slovenian medical journal = journal of Slovenian Medical Association. - ISSN 1318-0347 (Letn. 81, št. 4, apr. 2012, str. 304-311)Vrsta gradiva - članek, sestavni delLeto - 2012Jezik - slovenskiCOBISS.SI-ID - 29870041
Avtor
Černelč, Peter |
Kodre, Veronika
Teme
Multiple Myeloma |
Therapy |
Drug Therapy |
Dexamethasone |
Antibodies, Monoclonal |
Bence Jones Protein |
Proteinuria |
Kidney Failure |
Hematopoietic Stem Cell Transplantation |
Treatment Outcome |
Retrospective Studies |
Protitelesa monoklonska |
Bence Jonesova beljakovina |
Proteinurija |
Multipli mielom |
Deksametazon |
Ledvična odpoved |
Hematopoetska matična celica, presaditev |
Retrospektivne študije |
Zdravljenje, izid
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Černelč, Peter | 07012 |
Kodre, Veronika | ![]() |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.